Table 2

ROI figures from national NCD investment cases (over a 15-year period)

CountryTobaccoAlcoholSaltPhysical activityClinical intervention package for CVD and diabetes
Armenia14.54.114.34.40.3
Barbados*Package warnings: 38
Advertising bans: 26
Cessation programmes: 11
NANANACVD
Combination drug therapy for those at CVD risk: 15.5
Drug therapy for those with hypertension: 0.7
Drug therapy for those with high cholesterol: 1.9
Aspirin post-acute stroke: 15.5
Combination drug therapy for those with IHD: 31
Combination drug therapy for those with stroke: 37.5
Diabetes
Standard glycaemic control: 0.3
Intensive glycaemic control: 1.1
Cambodia10.75.09.610.00.2
Ethiopia3.11.43.31.80.1
Jamaica5.371.86NANACVD: 1.9
Diabetes: 2.1
Kyrgyzstan3.8NA12.33.6CVD: 0.01
Philippines8.87.029.912.70.1
Russian Federation†NANANANANA
Thailand2.532.2810.261.821.25
Türkiye5.00.688.02.34.3
Uganda†NANANANANA
Uzbekistan13.01.964.89.60.3
Zambia5.31.3NA4.54.6
  • *The capacity to calculate ROI for a number of policy options was not available at the time of undertaking the analysis in Barbados. In addition, ROI analysis was broken down by specific interventions, rather than by intervention package.

  • †ROI figures not publicly available at the time of writing.

  • CVD, cardiovascular disease; IHD, ischaemic heart disease; NA, not available; NCD, non-communicable disease; ROI, return on investment.